Ependymoma: Evaluation and Management Updates

Roberta Rudà1 · Francesco Bruno1 · Alessia Pellerino1 · Riccardo Soffietti1

Accepted: 18 February 2022 / Published online: 6 April 2022 © The Author(s) 2022

Abstract

Purpose of Review To review state of art and relevant advances in the molecular genetics and management of ependymomas of children and adults.

Recent Findings Ependymomas may occur either in the brain or in the spinal cord. Compared with intracranial ependymomas, spinal ependymomas are less frequent and exhibit a better prognosis. The new WHO classification of CNS tumors of 2021 has subdivided ependymomas into different histomolecular subgroups with different outcome. The majority of studies have shown a major impact of extent of resection; thus, a complete resection must be performed, whenever possible, at first surgery or at reoperation. Conformal radiotherapy is recommended for grade 3 or incompletely resected grade II tumors. Proton therapy is increasingly employed especially in children to reduce the risk of neurocognitive and endocrine sequelae. Craniospinal irradiation is reserved for metastatic disease. Chemotherapy is not useful as primary treatment and is commonly employed as salvage treatment for patients failing surgery and radiotherapy.

Summary Standard treatments are still the mainstay of treatment: the discovery of new druggable pathways will hopefully increase the therapeutic armamentarium in the near future.

Keywords Supratentorial ependymomas · Posterior fossa ependymomas · Spinal cord ependymomas · ZFTA fusion-positive ependymoma · YAP-1 fusion-positive ependymoma · Posterior fossa A · Posterior fossa B · MYCN-amplified spinal ependymoma · Myxopapillary ependymoma · Surgery · Conformal radiotherapy · Stereotactic radiotherapy · Proton therapy · Chemotherapy

Introduction

Ependymomas are neuroepithelial tumors that may arise from the ependymal cells of the cerebral ventricles, the central canal of the spinal cord, or cortical rests. According to the Central Brain Tumor Registry of the USA, the annual incidence of ependymomas ranges from 0.29 to 0.6 per 100,000 persons [1]. These tumors account for 1.6–1.8% of all primary CNS tumors: in children they are proportionally more common being 5.2%, while in adults are around 4%. Males are slightly more affected than females (1.3:1). Tumor location is largely dependent on patient age, with approximately 90% of pediatric ependymomas occurring intracranially, and 65% of adult tumors occurring in the spinal cord [2].

Given the low incidence, the literature regarding intracranial ependymomas in adults is sparse, as most series combine pediatric and adult ependymomas, grade II and grade III tumors, are retrospective, include limited numbers of patients, and span several decades in which diagnostic and therapeutic modalities have changed. Conversely, more information is available in ependymomas of children, and commonly therapeutic strategies in adults follow those in children [3].

In recent years, the molecular changes in ependymoma have undergone extensive analysis: the studies have provided new insight to define the origin of the ependymoma stem
pared with that of PFB ependymomas [8].

A recent molecular classification has distinguished 9 subgroups of ependymomas that appear to reflect more precisely than histology alone the biological, clinical, and histopathological heterogeneity across the major anatomical compartments, age groups, and tumor grades and have represented the basis for the update of World Health Organization (WHO) classification from 2016 to 2021 [8–10, 11••].

The New WHO Classification of 2021

According to the WHO classification of CNS tumors of 2021 [11••], when possible, ependymomas should be classified according to a combination of histological and molecular features across three tumor locations (supratentorial, infratentorial and spinal). One group at each anatomical site consists of tumors with the morphological features of subependymoma (WHO grade 1), that is often asymptomatic, discovered only incidentally on neuroimaging and carries an excellent prognosis.

In the supratentorial compartment, there are two other groups with different molecular features, clinical characteristics and outcome, i.e., the supratentorial ependymoma ZFTA fusion-positive and the supratentorial ependymoma YAP1 fusion-positive. The first one accounts for the majority of supratentorial ependymomas and may occur both in children and adults. The second one is uncommon and restricted to young children. In terms of prognosis, a retrospective study reported a poorer survival for ST-RELA [8], while in trial-based analyses of pediatric cohorts, RELA-fusion status was not found to be prognostic [12•, 13, 14•]. The ST-YAP1 fusion-positive ependymoma seems to carry a favorable prognosis [13, 15•]. Unlike ST ependymomas, posterior fossa ependymomas lack recurrent fusions, while methylation profiling has identified two main subgroups, i.e., posterior fossa A (PFA) and B (PFB). Moreover, the level of histone H3K27-trimethylation is high in PFB but low in PFA tumors. Gain of 1q has been shown across multiple studies to be a highly prognostic independent marker of a poor outcome in PFA ependymomas [12•, 14•, 15•] but not in PFB ependymomas [16]. In general, additional molecular heterogeneity within PFA ependymomas is being discovered [17••]. PFA ependymomas occur mainly in infants and children, while PFB ependymomas arise mainly in adolescents and adults. PFA ependymomas have a poor prognosis compared with that of PFB ependymomas [8].

In the spinal cord, classical ependymomas (WHO grade 2 and 3) and myxopapillary ependymomas (WHO grade 2) predominate among adults and thus far are not stratified molecularly: they are often relatively indolent tumors, while a rare and highly aggressive subgroup with a propensity to disseminate, affecting young adults and adolescents, the spinal ependymoma, MYCN-amplified, has been recently identified [18, 19•]. Due to the unfavorable prognosis, now, this tumor type should be distinguished from the other two spinal subgroups to guide clinical management.

Overall, despite the classification of ependymomas moving towards a molecular diagnosis, the WHO grading system still holds prognostic value, especially the distinction of grades 2 and 3 in intracranial ependymomas, and can help guide treatment decisions [20]. This is particularly true for only histologically defined tumors, when a canonical molecular signature is absent, when the molecular definition is uncertain due to the presence of mutations of unknown significance, or in places where molecular testing is not available.

Neuroimaging for Diagnosis and Monitoring

MRI with contrast enhancement is the modality of choice for diagnosing ependymal tumors [21, 22]. CT can better depict calcifications, which are most commonly observed in subependymomas.

Intracranial ependymomas commonly appear as well-circumscribed mass lesions and have a heterogeneous appearance on T1-, T2-, and post-contrast magnetic resonance imaging (MRI), displaying varying degrees of contrast enhancement. Advanced imaging modalities may assist in diagnosis. Diffusion-weighted imaging may be useful for differentiating pilocytic astrocytomas, medulloblastomas, and ependymomas in the posterior fossa [23]. MR spectroscopy reveals elevated choline and reduced N-acetylaspartate levels [6]. Perfusion MRI may display elevated cerebral blood volume values and have some prognostic value [24].

Spinal cord ependymomas display more distinct borders than diffuse astrocytomas [25]. Cyst formation and T2 hypointensity of the cyst wall due to blood products (“hemosiderin cap”) are suggestive of ependymoma, and an associated syringomyelia is common.

Myxopapillary ependymoma (MPE) is typically located in the conus medullaris, cauda equina, and filum terminale region.

Surveillance with MRI may detect recurrences in asymptomatic patients for earlier salvage therapies, resulting in superior 3-year progression free survival (PFS), but the impact on overall survival (OS) is still limited [26•]. It is still not clear how often and for how long surveillance is needed [27]; however, due to the possibility of late recurrences, long-term follow-up is standard.
Management of Newly Diagnosed Intracranial Ependymomas in Children

Gross total resection is the mainstay of treatment with an OS of at least 70% at 5 years [7•, 14•, 28, 29]. The possibility of avoiding adjuvant radiotherapy has been explored in the ACNS0121 trial [12•]: 11 patients with completely resected supratentorial tumors of WHO grade 2 were observed with MRI, achieving a 5-year PFS of 61.4% and OS of 100%. The likelihood of a GTR is greater for supratentorial tumors than for infratentorial ones. Tumors arising from the floor and the lateral portion of the IV ventricle have a higher risk of postoperative deficits as compared to those arising from the roof, and subtotal resections are more often performed with the consequence of a lower OS. Due to the prognostic value of GTR, a second-look surgery is increasingly employed in case the first resection did not achieve a GTR, commonly when the surgical procedure was performed in an emergency situation or in a non-skilled institution [30, 31].

The benefit of postoperative radiotherapy for incompletely resected ependymomas in terms of local control and overall survival rates is clear [12•, 29, 32]. The postoperative radiotherapy of 59.4 Gy (1.8 Gy/fraction) in grade 3 and grade 2 incompletely resected tumors is recommended [32] for children older than 3 years, while for children as young as 18 months or children with altered neurological status, the doses can be lowered to 54 Gy [33]. This can be true even for children between 12 and 18 months. A recent retrospective study on 206 patients reported that the main pattern of relapse is within the radiation fields even at 59.4 Gy [34]. A hypofractionated stereotactic boost in addition to conventional radiotherapy has been proposed to increase the efficacy [35]. A prospective study showed that hyperfractionated radiotherapy is safe but provides no outcome benefit compared with a standard fractionated regimen [36].

The toxicity of radiotherapy in younger children is of concern, and intensity-modulated radiation therapy is employed to limit late sequelae [37]. Proton therapy could be an alternative to conventional photon radiotherapy for toxicity reduction [38]. Reducing neurocognitive dysfunction, hearing loss, and neuroendocrine deficits is an important priority, especially for young children. Proton therapy may offer disease control commensurate with modern photon therapy [39, 40•]. A recent study evaluating proton therapy [40•] reported a 7-year local control, progression-free survival, and overall survival rates of 77%, 64%, and 82%, which are comparable to values reported by a parallel study with photon therapy (72%, 60%, and 79%) [12•]. The rates of symptomatic brain stem toxicity (4%), vascuropathy (1.8%), hearing loss (5%), and hormone deficiency (12%) with proton therapy appear slightly lower than those observed with conventional radiotherapy.

The role of chemotherapy in children remains unproven despite intensive investigation [41]. As there is reluctance to deliver radiation to very young children, postoperative chemotherapy is frequently proposed, while in older children, chemotherapy is delivered as an adjunct to radiotherapy. In prospective clinical trials, postoperative chemotherapy using various combinations of etoposide, vincristine, cyclophosphamide, platinum derivatives, and high-dose methotrexate demonstrated a 40 to 50% response rate [37, 42–44].

Intensified chemotherapy schedules have been suggested in infants [43], especially for those with supratentorial tumors [45]. In contrast, the use of immediate postoperative high-dose conformal radiotherapy in children under the age of 3 years is being investigated, but long-term follow-up for toxicity is still pending. Overall, radiotherapy deferral strategies by using chemotherapy for children aged more than 12 months have been abandoned also due to inadequate tumor control by chemotherapy.

Thus far, no targeted therapies are available in ependymomas. A recent preclinical study has suggested FGFR inhibition as a novel approach to target aggressive ependymomas [46].

Management of Newly Diagnosed Intracranial Ependymomas in Adults

Surgery is the first step of standard treatment. In the majority of studies, the extent of resection has emerged as one of the most significant predictors of outcome [2, 47–52, 53•]. In a retrospective series of WHO grade 2 ependymomas in adults [51], gross total resection (GTR) and infratentorial location were associated with a longer OS. GTR and tumor location were also independent factors predicting progression-free survival (PFS). Conversely, incomplete resection has an increased risk of tumor recurrence and CSF dissemination. However, in posterior fossa tumors, encasement of the cranial nerves and brainstem vasculature might limit extent of tumor resection [54].

In the past, patients with ependymoma often received craniospinal irradiation. However, numerous studies demonstrated the efficacy of local fields in the treatment of ependymoma, achieving good local control with low risk of spinal dissemination [55, 56•]. In adults, there is agreement that postoperative radiotherapy should be included in the standard of care for patients with anaplastic ependymoma (WHO grade 3) and for patients with ependymomas (WHO grade 2) after an incomplete resection [49, 57]. Conversely, the role of postoperative radiotherapy in patients with ependymoma WHO grade 2 undergoing GTR remains controversial [58].

Chemotherapy has no role in the adjuvant setting of newly diagnosed intracranial ependymomas of the adult.
Tailoring Treatment to Molecular Subgroups

Thus far, there are no data from prospective clinical studies tailored to the different molecular subgroups. Some hypotheses, generated in retrospective translational studies, need validation in clinical trials. Among supratentorial ependymomas, the subgroup with YAP1 fusion, which displays an excellent prognosis, could be observed without further therapy after resection. The same could be true for posterior fossa B tumors, in which also a de-escalation of RT could be considered. Conversely, posterior fossa A ependymomas are aggressive tumors, and the role of adjuvant radiotherapy after complete resection should be considered. Moreover, a recent study showed that tumor cells with increased EZHIP expression, which is considered as an important oncogenic driver in PFA, suppress DNA repair and respond to PARP inhibitors, especially when associated with radiotherapy [59]. Whether supratentorial ependymomas with RELA fusion need more intensive treatment is unknown and should be investigated.

Management of Recurrent Intracranial Ependymomas

Primary therapies for intracranial ependymomas, especially in children, are insufficient to prevent tumor recurrence. The majority of recurrences develop within the first 2 years of diagnosis; however, some of them occur many years later. Overall, there is no consensus on the best approach. Unfortunately, there have been no recent novel treatments on the horizon, apart from CAR-T cell therapy, which is still at the beginning [60].

The extent of resection at recurrence appears important in improving the outcome [61–63].

A recent study in children and adolescents [64] has reported that gross- and near-total resection were achieved in 64% of patients and were associated with an improved 5-year survival (OS) of 48.7% vs 5.3% in less than gross total or near-total resection.

There is also evidence that reirradiation may be beneficial in both adults and children at time of recurrence, using either conventionally fractionated irradiation or stereotactic irradiation or proton therapy [65–69]. The efficacy is more evident following incomplete resection [64], but the duration of control could be limited in time [63, 70].

Phase II studies in children with relapsing ependymomas have reported low response rates with either standard [71] or high-dose chemotherapy [72]. Metronomic therapies may yield long-term control [73]. Oral etoposide [74] or temozolomide (TMZ) [75] may yield some responses. Bevacizumab, in association with either irinotecan [76] or lapatinib [77], does not seem to be active. Targeted agents, such as erlotinib and sunitinib [74, 78], did not show any activity in an unselected series of patients.

Chemotherapy for recurrent ependymoma in adults is considered only when local options (surgery and radiotherapy) have been exhausted [3, 65, 79].

Similar to diffuse gliomas, TMZ has been used for the treatment of adult patients with ependymoma. A retrospective study conducted by Rudà et al. included 18 patients with recurrent WHO grade 2 and 3 intracranial ependymomas failing re-operation and/or re-irradiation, suggested an efficacy of TMZ in the standard schedule in terms of response (22% complete + partial) and survival (PFS 9.69 months and OS 30.55 months) [80]. Responses were observed in chemotherapy-naïve patients and tended to be delayed. Conversely, in another retrospective study conducted by Chamberlin et al. of patients with WHO grade 2 intracranial ependymomas refractory to first-line chemotherapy with platinum compounds [81], TMZ in the standard schedule had a limited efficacy with a response rate of 4%, a PFS of 2 months, and OS of 3 months. One must take into account that in the cohort of Chamberlain [81], patients were heavily pretreated, while the majority of patients in the cohort of Rudà [80] were chemo-naïve, thus receiving TMZ in an earlier phase of the disease. Temozolomide has also been used in combination with lapatinib in a single-arm phase II study in patients with recurrent intracranial and spinal ependymomas [82]. Lapatinib targets the epidermal growth factor receptors (ErbB1 and ErbB2), which may be expressed by ependymoma cells. Fifty patients were enrolled with a median PFS of 45 weeks for patients with WHO grade 2 tumors and 25.3 weeks for patients with WHO grade 3 ependymomas. Responses to treatment correlated with higher ErbB2 mRNA expression in tumor tissue. The modest activity of TMZ against ependymoma cells has been suggested to be due to the lack of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation [83, 84]; however, even when present, MGMT promoter methylation does not correlate with response to TMZ [80].

Platinum-based regimens seem superior over nitrosourea-based regimens [85]. A retrospective series reported higher response rates in patients with progressive or recurrent ependymoma treated with cisplatin compared with non-platinum regimens, but no difference in terms of PFS and OS was observed [86]. The anti-angiogenic agent bevacizumab has been employed in 8 patients with recurrent WHO grade 2 or 3 adult intracranial ependymoma with a median PFS of 6.4 months and OS of 9.4 months [87].

Table 1 summarizes the ongoing clinical trials in recurrent ependymomas.
Management of Spinal Cord Ependymomas

Spinal ependymoma (grade 2 or 3) has a better outcome than spinal astrocytoma. GTR offers the best prognosis [88•]. Advances in microsurgical techniques allow en bloc GTR over piecemeal subtotal resection (STR) as standard of care for spinal ependymomas with good functional results. Resection should be considered at an early stage of the disease as functional outcome is related to small tumor size and good neurological status at the time of surgery [89•, 90]. When GTR is not feasible, postoperative conformal radiotherapy is employed. A review of the literature on 348 patients with WHO grades 2 and 3 spinal ependymomas [91] has shown that the extent of resection and tumor grade were independent prognostic factors for OS and PFS, and radiotherapy prolonged PFS in patients receiving STR. Median PFS was 48 months in patients treated with STR alone and 96 months for patients treated with STR followed by radiotherapy. Studies suggest doses of ≥ 50 Gy [91].

Spinal ependymoma with MYCN amplification has a poor prognosis, but it is unknown what is the best therapeutic management for this subtype. Strategies for MYCN inhibition are being investigated, including vaccination [92].

Continuous oral etoposide is well tolerated and may be active in recurrent intramedullary ependymoma; also, bevacizumab can provide clinical benefit in some patients [93].

Large retrospective series on MPE are available. A multi-institutional series of 183 patients [94] showed a 10-year OS of 92.4% and a 5- and 10-year PFS of 69.5% and 61.2%. Recurrence was local in 84% of patients, while leptomeningeal spread occurred in 9.3% of patients. An OS at 10 years exceeding 90% has been recently confirmed in an analysis by the Surveillance, Epidemiology, and End Results (SEER) program of 773 patients [95].

Surgical resection is the mainstay of treatment for MPE, and the extent of resection is the most important prognostic factor [94, 96, 97, 98•]. However, due to a close adhesion to the nerve roots and production of a myxoid matrix, a safe GTR of MPE may be challenging: in fact, the rate of GTR in the literature ranges from 53 to 75% [98•, 99•]. A systematic review of the literature [100] found that the recurrence rate after GTR (15.5%) was significantly lower than that after STR (32.6%), while being higher in pediatric patients as compared to adults (40.5% vs 23.4%). The role of radiotherapy for MPE in adults is still controversial. Adjuvant radiotherapy was not associated with a decrease in the recurrence rates in the review of Feldman et al. (2013), while other series reported a superiority for combined surgery and postoperative radiotherapy over surgery alone [96, 99•, 101]. In particular, the experience of MD Anderson Cancer Center [96] showed that the addition of postoperative radiotherapy to surgery was associated with significantly

### Table 1: Ongoing clinical trials in recurrent / progressive ependymomas

| NCT number   | Type of study | No. of patients | Type of treatment                                                                 | Estimated study completion |
|--------------|---------------|----------------|-----------------------------------------------------------------------------------|----------------------------|
| NCT02155920 | Phase 2       | 11 patients with recurrent or progressive grade 2–3 ependymomas | Everolimus 4.5 mg/m²/dose once daily                                                | December 30, 2021          |
| NCT04958486 | Early phase 1 | 10 children and adults with recurrent or residual posterior fossa ependymoma | 5-azacytidine and trastuzumab infusions into the fourth ventricle or resection cavity | July 5, 2023               |
| NCT01795313 | Phase 1       | 24 patients aged 1–21 years with recurrent ependymomas (any grade) | HLA-A2 restricted tumor antigen peptide vaccine plus imiquimod                     | December 31, 2023          |
| NCT03572530 | Phase 1       | 9 patients aged 1–80 years with recurrent ependymomas | 5-azacytidine infusions into the fourth ventricle Arm 1: 3 times per week Arm 2: 2 times per week Arm 3: 1 time for week | July 1, 2022               |
| NCT02774421 | Phase 1       | 33 patients aged 1–21 years with recurrent posterior fossa ependymomas | intrathecal trastuzumab in combination plus subcutaneous granulocyte–macrophage colony-stimulating factor | March 1, 2022              |
| NCT03033992 | Not applicable | 25 patients with recurrent or progressive supratentorial malignant gliomas and ependymomas | Tumor treating fields device                                                        | September 30, 2022         |
| NCT04661384 | Phase 1       | Leptomeningeal metastases from ependymomas | IL13Ralpha2-CAR T cells                                                             | December 15, 2023          |
| NCT02359565 | Phase 1       | 100 children with recurrent or progressive diffuse intrinsic pontine glioma, high-grade gliomas, ependymomas, medulloblastomas or hypermutated brain tumors | Pembrolizumab every 21 days                                                        | December 31, 2024          |
longer 10-year PFS rates (75% for the combination vs 37% for surgery alone).

MPE is very rare in children. Pediatric patients frequently present with disseminated tumor and/or develop recurrent or progressive disease following treatments [102], though the OS at 5 and 10 years in the SEER database is estimated at 97% and 95%, respectively [103]. Recent small studies suggested a better local control after surgery and postoperative radiotherapy [104, 105].

In general, the definitive role of radiotherapy still needs further studies. The irregular shape, contact with surrounding nerve roots, and production of a myxoid matrix, particularly in the filum terminale, can make GTR particularly challenging with risks of postoperative neurological disability. A strong correlation between capsular violation at surgery and recurrence has been found [97]. Considering the non-negligible risk of recurrence and spinal dissemination of MPE, radiotherapy should be recommended for patients undergoing largely incomplete resections, even if there is some risk of post-irradiation radiculopathy in long-term survivors.

Conclusions

Recent translational studies show that most ependymomas have a similar appearance using conventional microscopy but vary widely in the genetic alterations that likely led to tumorigenesis and subsequent tumor biology. Most studies demonstrate a major impact of GTR on survival outcomes, despite small patient numbers limiting reliable multivariate analyses. For incompletely resected intracranial grade 2 tumors, postoperative radiotherapy is recommended. The predominant pattern of relapse is local; thus, it is important for all patients to undergo complete resection when possible and a “second surgery” for those with initial incomplete resection. The benefit of radiotherapy could be enhanced by dose escalation using modern techniques such as proton therapy. CSI could be useful in patients with leptomeningeal spread. A better knowledge of molecular pathways of tumor progression is needed to develop novel targeted agents. Multi-institutional and international studies are necessary to tailor the different therapeutic options to the different molecular subgroups.

Funding Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement.

Declarations

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:

● Of importance

● Of major importance

1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1-iv96.
2. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg. 2009;110(4):725–9.
3. Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 2018;20(4):445–56.
4. Wani K, Armstrong TS, Vera-Bolanos E, et al; Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012;123(5):727–738.
5. Raghunathan A, Wani K, Armstrong TS, et al; Collaborative Ependymoma Research Network. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol. 2013;23(5):584–594.
6. Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 2016;18(7):902–13.
7. ● Junger ST, Timmermann B, Pietsch T. Pediatric ependymoma: an overview of a complex disease. Childs Nerv Syst. 2021;37(8):2451–63. (An exhaustive overview of molecular and therapeutic aspects of pediatric ependymomas.)
8. Pajtler KW, Witt H, Sill M, Jones DT, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–43.
9. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
10. Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 2020;30(5):863–6.
11. ● Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. (The new WHO classification of CNS tumors, including ependymomas.)
12. Merchant TE, Bendel AE, Sabin ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol. 2019;37(12):974–83. (A clinical trial reporting the value of observation after complete resection of supratentorial pediatric ependymomas.)

13. Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYCO7 trial. Neuro Oncol. 2019;21(10):1319–30.

14. Massimino M, Barretta F, Modena P, et al. Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro Oncol. 2021;23(5):848–57. (A multi-institutional study reporting long-term results of intracranial pediatric ependymomas.)

15. Andreioulo F, Varlet P, Tazie-Moyri A, et al. Childhood supratentorial ependymomas with YAP1-MAML1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathol. 2019;29(2):205–16. (First description of supratentorial YAP1 fusion ependymoma.)

16. Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PP–EPN–B ependymoma subgroup. Acta Neuropathol. 2018;136(2):227–37.

17. Baroni LV, Sundaresan L, Heled A, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1360–70. (Study suggesting a molecular subdivision of posterior fossa ependymoma of type A.)

18. Swanson AA, Raghunathan A, Jenkins RB, et al. Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol. 2019;78(9):791–7.

19. Raffeld M, Abdullaev Z, Pack SD, et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun. 2020;8(1):101. (Study describing extensively the molecular characteristics of MYCN amplified spinal ependymoma.)

20. Lopez-Rivera V, Dono A, Abdelkhaled R, et al. Treatment trends and overall survival in patients with grade II/III ependymoma: the role of tumor grade and location. Clin Neurol Neurosurg. 2020;199:106282.

21. Yuh EL, Barkovich AJ, Gupta N. Imaging of ependymomas: the first prospective AIEOP study. Int J Radiat Oncol Biol Phys. 2016;95(1):267–78.

22. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Rysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95(1):267–78.

23. Sato M, Gunther JR, Mahajan A, et al. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017;123(13):2570–8.

24. Indelicato DJ, Ioakim-Ioannidou M, Bradley JA, et al. Proton therapy for pediatric ependymoma: mature results from a bicentric study. Int J Radiat Oncol Biol Phys. 2021;109(3):815–20. (Detailed multicenter retrospective study on efficacy and adverse events of proton therapy in pediatric ependymomas.)

25. Klawinski D, Indelicato DJ, Hossain J, Sandler E. Surveillance imaging in pediatric ependymoma. Pediatr Blood Cancer. 2020;67(11):e28622. (The unique study describing surveillance neuroimaging in pediatric ependymomas.)

26. Good CD, Wade AM, Hayward RD, et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? J Neurosurg. 2001;94(1):27–32.

27. Raffeld M, Abdullaev Z, Pack SD, et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of cervical ependymoma. J Neuropathol Exp Neurol. 2012;106(2):367–75.

28. Massimino M, Miceli R, Giangaspero F, et al. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol. 2016;18(10):1451–60.

29. Cossetti F, Ducassou A, Chaltiel L, et al; radiotherapy committee of the French Society for Childhood Cancer (SFCE). Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiother Oncol. 2017;122(3):362–367.

30. Aggarwal R, Yeung D, Kumar P, Muhlbaier M, Kun LE. Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiat Oncol. 1997;43(3):269–73.

31. Conter C, Carrie C, Bernier V, et al. Intracranial ependymomas in children: Society of Pediatric Oncology experience with postoperative hyperfractionated local radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(5):1536–42.

32. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for pediatric ependymoma: a prospective study. Lancet Oncol. 2009;10(3):258–66.

33. Koshy M, Rich S, Merchant TE, Mahmood U, Regine WF, Kwok Y. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol. 2011;105(3):583–90.

34. Tensaouti F, Ducassou A, Chaltiel L, et al; radiotherapy committee of the French Society for Childhood Cancer (SFCE). Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiother Oncol. 2017;122(3):362–367.

35. Massimino M, Gandola L, Giangaspero F, et al; AIEOP Pediatric Neuro-Oncology Group. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Epatologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004;58(5):1336–1345.

36. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Rysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95(1):267–78.

37. Sato M, Gunther JR, Mahajan A, et al. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017;123(13):2570–8.

38. Indelicato DJ, Ioakim-Ioannidou M, Bradley JA, et al. Proton therapy for pediatric ependymoma: mature results from a bicentric study. Int J Radiat Oncol Biol Phys. 2021;109(3):815–20. (Detailed multicenter retrospective study on efficacy and adverse events of proton therapy in pediatric ependymomas.)

39. Khatua S, Ramaswamy V, Bouffet E. Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer. 2017;70:34–41.

40. Indelicato DJ, Ioakim-Ioannidou M, Bradley JA, et al. Proton therapy for pediatric ependymoma: mature results from a bicentric study. Int J Radiat Oncol Biol Phys. 2021;109(3):815–20. (Detailed multicenter retrospective study on efficacy and adverse events of proton therapy in pediatric ependymomas.)

41. Klawinski D, Indelicato DJ, Hossain J, Sandler E. Surveillance imaging in pediatric ependymoma. Pediatr Blood Cancer. 2020;67(11):e28622. (The unique study describing surveillance neuroimaging in pediatric ependymomas.)

42. Grill J, Le Deley MC, Gambarelli D, et al; French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multi-center trial of the French Society of Pediatric Oncology. J Clin Oncol. 2001;19(5):1288–1296.
51. Metellus P, Guyotat J, Chinot O, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol. 2010;12(9):976–84.

52. Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. J Neurosurg. 2016;125(2):410–8.

53. Zhao F, Wu T, Wang LM, Zhang J, Zhang H, Li SW, Zhang S, Li P, Wang B, Luo L, Liu PN. Survival and prognostic factors of adult intracranial ependymoma: a single-institutional analysis of 236 patients. Am J Surg Pathol. 2021;45(7):979–87. (A huge retrospective analysis of outcome in adult intracranial ependymoma.)

54. Spagnoli D, Tomei G, Ceccarelli G, et al. Combined treatment of fourth ventricle ependymomas: report of 26 cases. Surg Neurol. 2000;54(1):19–26; discussion 26.

55. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: a prospective study. J Neurooncol. 2002;56(1):285–91.

56. Lötsc h D, Kirchhofer D, Engelinger B, et al. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021;142(2):339–60.

57. Grundy RG, Wilne SA, Weston CL, et al; Children’s Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8(8):696–705.

58. Garvin JH Jr, Selch MT, Holmes E, et al; Children's Oncology Group. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1183–1189.

59. Venkatramani R, Ji L, Lasky J, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neurooncol. 2013;113(2):285–91.

60. Han J, Yu M, Bai Y, et al. Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell. 2020;38(6):844–856.e7.

61. Donovan LK, Dela i dell A, Joseph SK, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26(5):720–31. (First report of a CAR T-cells immunotherapy for metastatic ependymoma.)

62. Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frappaz D. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst. 2010;26(7):905–11.

63. Marinoff AE, Ma C, Guo D, et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017;135(1):201–11.

64. Ritzmann TA, Kilday JP, Grundy RG. Pediatric ependymomas: destined to recur? Neuro Oncol. 2021;23(6):874–6.

65. Abou El-Azmel M, Fouladi M, Turner DC, et al. An open-label, two-arm phase II trial of temsirolimus and temozolomide in pediatric patients with recurrent or refractory ependymoma: a Collaborative Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–75.
Ependymoma Research Network study (CERN). J Neurooncol. 2015;123(1):85–91.
78. Wetmore C, Daryani VM, Billups CA, et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a Children’s Oncology Group study ACNS1021. Cancer Med. 2016;5(7):1416–24.
79. Iqbal MS, Lewis J. An overview of the management of adult ependymomas with emphasis on relapsed disease. Clin Oncol (R Coll Radiol). 2013;25(12):726–33.
80. Rudi R, Bosa C, Magistrello M, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 2016;18(2):261–8.
81. Chamberlain MC, Johnston SK. Temozolomide for recurrent intracranial ependymomas. Neuro Oncol. 2009;11(5):4775–82.
82. Gilbert MR, Yuan Y, Wani K, et al. A phase II study of lapatinib and dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial [Abstract]. Neuro Oncol. 2014;16(5):AT-23.
83. Buccoliero AM, Castiglione F, Rossi Degl’Innocenti D, et al. O6-methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother. 2008;20(2):263–268.
84. Gramatzki D, Roth P, Felsberg J, et al. Chemotherapy for intracranial supratentorial platinum-refractory ependymoma. Cancer. 2009;115(20):4775–82.
85. Chamberlain MC, Johnston SK. Chemotherapy for intracranial ependymoma. J Neurooncol. 2016;129(2):251–8.
86. Gilbert MR, Yuan Y, Wani K, et al. A phase II study of lapatinib and dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial [Abstract]. Neuro Oncol. 2014;16(5):AT-23.
87. Wetmore C, Daryani VM, Billups CA, et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a Children’s Oncology Group study ACNS1021. Cancer Med. 2016;5(7):1416–24.
88. Deng Y, Chen H, Wang C, Zhang Y. Risk factors for the recurrence of world health organization grade II ependymomas of spinal cord in adults after microsurgical resections: a retrospective study of 118 patients in a single center. Clin Neurol Neurosurg. 2020;195:105856. (A huge retrospective study on the impact of modern surgery in grade 2 ependymomas of adults.)
89. Eroes CA, Zaussinger S, Kreth FW, Goldbrunner R, Tonn JC. Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome. Acta Neurochir (Wien). 2010;152(4):611–618. (Retrospective analysis of prognostic factors in intramedullary low grade ependymomas.)
90. Lin Y, Smith ZA, Wong AP, Melkonian S, Harris DA, Lam S. Predictors of survival in patients with spinal ependymoma. Neuro Oncol. 2015;17(4):650–5.
91. Oh MC, Ivan ME, Sun MZ, et al. Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. Neuro Oncol. 2013;15(2):208–15.
92. Stermann A, Huebener N, Seidel D, et al. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother. 2015;64(10):1215–27.
93. Chamberlain MC. Ependymomas. Curr Neurol Neurosci Rep. 2003;3(3):193–9.
94. Weber DC, Wang Y, Miller R, et al. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol. 2015;17(4):588–95.
95. Bates JE, Choi G, Milano MT. Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neurooncol. 2016;129(2):251–8.
96. Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol. 2006;80(2):177–183.
97. Abdulaziz M, Mallory GW, Bydon M, et al. Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus. 2015;39(2):E8.
98.● Montero AS, Tran S, Amelot A, et al. Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients. J Neurooncol. 2021;152(3):491–9. (Multi-institutional study on outcome of myxopapillary spinal ependymoma.)
99.● Liu T, Yang C, Deng X, et al. Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas. Neurosurg Rev. 2020;43(5):1351–6. (Retrospective analysis of outcome after surgery for myxopapillary ependymoma.)
100.● Feldman WB, Clark AJ, Saface M, Ames CP, Parsa AT. Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine. 2013;19(4):471–6.
101. Schild SE, Wong W, Nisi K. In regard to the radiotherapy of myxopapillary ependymomas. Int J Radiat Oncol Biol Phys. 2002;53(3):787.
102. Bandopadhyay P, Silvera VM, Ciarlini PDSC, et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016;126(1):165–74.
103. Luchesi KM, Grant R, Kahle KT, Marks AM, DiLuna ML. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. J Neurooncol. 2016;130(1):133–40.
104.● Al-Halabi H, Montes JL, Atkinson J, Farmer JP, Freeman CR. Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas. Pediatr Blood Cancer. 2010;55(4):639–43.
105. Agbahiwe HC, Wharam M, Batra S, Cohen K, Terezakis SA. Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013;85(2):421–7.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.